281 related articles for article (PubMed ID: 33547368)
41. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
[TBL] [Abstract][Full Text] [Related]
43. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Nowakowski GS; Witzig TE
Clin Adv Hematol Oncol; 2006 Mar; 4(3):225-31. PubMed ID: 16728934
[TBL] [Abstract][Full Text] [Related]
44. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
45. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
46. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
Ponvilawan B; Vittayawacharin P; Tunsing P; Owattanapanich W
Technol Cancer Res Treat; 2021; 20():15330338211037434. PubMed ID: 34350787
[TBL] [Abstract][Full Text] [Related]
48. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
49. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
50. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
Tobinai K
Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
[TBL] [Abstract][Full Text] [Related]
51. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
52. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
Pérez-Callejo D; González-Rincón J; Sánchez A; Provencio M; Sánchez-Beato M
Cancer Treat Rev; 2015 Sep; 41(8):680-9. PubMed ID: 26045227
[TBL] [Abstract][Full Text] [Related]
53. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
54. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
Sohani AR; Maurer MJ; Giri S; Pitcher B; Chadburn A; Said JW; Bartlett NL; Czuczman MS; Martin P; Rosenbaum CA; Jung SH; Leonard JP; Cheson BD; Hsi ED
Am J Surg Pathol; 2021 Mar; 45(3):384-393. PubMed ID: 33136585
[TBL] [Abstract][Full Text] [Related]
55. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
56. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
57. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
58. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
59. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
Klein C; Jamois C; Nielsen T
Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
[TBL] [Abstract][Full Text] [Related]
60. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
